[HTML][HTML] Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - Elsevier
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
[PDF][PDF] Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - core.ac.uk
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients …
SM Gadgeel, JC Ruckdeschel… - Journal of thoracic …, 2007 - pubmed.ncbi.nlm.nih.gov
Background Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%-18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%-18% in relapsed non-small cell lung cancer (NSCLC) …
[HTML][HTML] Phase II Study of Gefitinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (EGFR-TKI), and Celecoxib, a Cyclooxygenase-2 (COX-2) Inhibitor …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - jto.org
Background: Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%–18% in relapsed non-small cell lung cancer (NSCLC) …
Phase II study of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and celecoxib, a cyclooxygenase-2 (COX-2) inhibitor, in patients …
SM Gadgeel, JC Ruckdeschel, EI Heath… - Journal of Thoracic …, 2007 - europepmc.org
Background Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has
demonstrated a response rate of 9%-18% in relapsed non-small cell lung cancer (NSCLC) …
demonstrated a response rate of 9%-18% in relapsed non-small cell lung cancer (NSCLC) …